Lannett Co Inc (LCI)
(Delayed Data from NYSE)
$8.54 USD
+0.70 (8.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.54 USD
+0.70 (8.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Lannett Co (LCI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LCI) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for Lannett (LCI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.
Top Ranked Value Stocks to Buy for May 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, May 16th
Lannett (LCI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Lannett (LCI) delivered earnings and revenue surprises of 9.68% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LCI) Outperforming Other Medical Stocks This Year?
Analysts Estimate Lannett (LCI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches
Are Options Traders Betting on a Big Move in Lannett (LCI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.
Lannett (LCI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Lannett (LCI) closed at $8.05 in the latest trading session, marking a +0.06% move from the prior day.
Has Lannett Co (LCI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LCI) Outperforming Other Medical Stocks This Year?
Lannett (LCI) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Lannett (LCI) closed at $7.91 in the latest trading session, marking a -0.75% move from the prior day.
Lannett (LCI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Lannett (LCI) closed at $7.56, marking a +1.2% move from the previous day.
New Strong Buy Stocks for March 26th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LCI) Outperforming Other Medical Stocks This Year?
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
by Zacks Equity Research
Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
by Zacks Equity Research
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
Should Value Investors Consider Lannett Company (LCI) Now?
by Zacks Equity Research
Let's see if Lannett Company (LCI) stock is a good choice for value-oriented investors right now from multiple angles.
Endo (ENDP) Soars: Stock Adds 6% in Session
by Zacks Equity Research
Endo (ENDP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Implied Volatility Surging for Lannett (LCI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.
Top Ranked Value Stocks to Buy for February 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 27th:
Top Ranked Value Stocks to Buy for February 26th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 26th:
Top Ranked Value Stocks to Buy for February 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 22nd
Top Ranked Value Stocks to Buy for February 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 20th
Top Ranked Value Stocks to Buy for February 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 12th